World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
73663
World Ranking
10636
National Ranking
382

Alba A. Brandes publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Alba A. Brandes sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 625 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Alba A. Brandes D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Alba A. Brandes sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 93 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Alba A. Brandes is affiliated with the Institute of Neurological Sciences in Italy. Their research spans multiple areas within medicine, biochemistry, genetics, and molecular biology, with a particular emphasis on oncology and cancer research.

Their scholarly work covers several specialized subfields, including:

  • Genetics
  • Oncology
  • Cancer Research
  • Pulmonary and Respiratory Medicine
  • Molecular Biology

Brandes's research primarily focuses on topics related to:

  • Glioma Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Cancer Genomics and Diagnostics
  • Meningioma and schwannoma management
  • Radiomics and Machine Learning in Medical Imaging
  • Cancer Immunotherapy and Biomarkers
  • Cancer, Hypoxia, and Metabolism

Their frequent publication venues provide insight into the academic platforms where their work appears most often. These include:

  • Neuro-Oncology
  • The Lancet Oncology
  • Expert Review of Anticancer Therapy
  • Journal of Clinical Oncology
  • Diagnostics

Brandes has collaborated extensively with several coauthors, highlighting ongoing research partnerships with:

  • Enrico Franceschi
  • Vincenzo Di Nunno
  • Lidia Gatto
  • Martin J. van den Bent
  • Wolfgang Wick

Among Brandes's recent publications are significant works including:

  • "Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma" (2020), published in JAMA Oncology
  • "Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial" (2022), published in Neuro-Oncology
  • "Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study" (2021), published in The Lancet Oncology
  • "Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group" (2020), published in The Lancet Oncology
  • "Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas" (2021), published in CNS Oncology

Best Publications

  • Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

    Roger Stupp;Warren P. Mason;Martin J. van den Bent;Michael Weller

  • Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

    Roger Stupp;Monika E. Hegi;Warren P. Mason;Martin J. van den Bent

  • Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

    Olivier L. Chinot;Wolfgang Wick;Warren Mason;Roger Henriksson

  • Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

    Martin J. van den Bent;Alba A. Brandes;Martin J.B. Taphoorn;Johan M. Kros

  • Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

    Roger Stupp;Roger Stupp;Monika E Hegi;Thierry Gorlia;Sara C Erridge

  • Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial

    David A. Reardon;Alba A. Brandes;Antonio Omuro;Paul Mulholland

  • Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

    James R. Perry;Normand Laperriere;Christopher J. O'Callaghan;Alba A. Brandes

  • Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial

    Martin J. van den Bent;Antoine F. Carpentier;Alba A. Brandes;Marc Sanson

  • MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

    Alba A. Brandes;Enrico Franceschi;Alicia Tosoni;Valeria Blatt

  • Lomustine and Bevacizumab in Progressive Glioblastoma

    Wolfgang Wick;Thierry Gorlia;Martin Bendszus;Martin Taphoorn

  • MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

    Michael Weller;Roger Stupp;Guido Reifenberger;Alba A. Brandes

  • Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

    Hideho Okada;Michael Weller;Raymond Huang;Gaetano Finocchiaro

  • High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

    Andrés J. M. Ferreri;Michele Reni;Marco Foppoli;Maurizio Martelli

  • Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

    Martin J. van den Bent;Alba A. Brandes;Roy Rampling;Mathilde C.M. Kouwenhoven

  • Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial

    René Olivier Mirimanoff;Thierry Gorlia;Warren Mason;Martin J. Van Den Bent

  • Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3

    Thierry Gorlia;Martin J van den Bent;Monika E Hegi;Monika E Hegi;René O Mirimanoff

  • Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

    Brigitta G Baumert;Brigitta G Baumert;Monika E Hegi;Martin J van den Bent;Andreas von Deimling

  • Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

    Martin J van den Bent;Brigitta Baumert;Sara C Erridge;Michael A Vogelbaum;Michael A Vogelbaum

  • Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971

    M J van den Bent;M J B Taphoorn;A A Brandes;Johan Menten

  • IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

    Martin J. van den Bent;Hendrikus J. Dubbink;Yannick Marie;Alba A. Brandes

Frequent Co-Authors

Martin J. van den Bent
Martin J. van den Bent Erasmus University Rotterdam
Wolfgang Wick
Wolfgang Wick German Cancer Research Center
Roger Stupp
Roger Stupp Northwestern University
Michael Weller
Michael Weller University of Zurich
Johan M. Kros
Johan M. Kros Erasmus University Rotterdam
Michele Reni
Michele Reni Vita-Salute San Raffaele University
Anna K. Nowak
Anna K. Nowak University of Western Australia
Giovanni Tallini
Giovanni Tallini University of Bologna
Monika E. Hegi
Monika E. Hegi University of Lausanne
Khê Hoang-Xuan
Khê Hoang-Xuan Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers beyond traditional medical school paths, several online degree options offer flexibility and career advancement. Many registered nurses look to increase their qualifications with adn to np programs online, allowing them to move from an associate-level nursing degree to becoming a nurse practitioner from anywhere.

If you are passionate about diet, wellness, and patient education, pursuing online degrees in nutrition can lead to rewarding roles in healthcare, public policy, or private practice.

For those aiming at healthcare administration, online mha programs cahme accredited ensure you receive a recognized credential, preparing you for leadership roles in hospitals or health systems.

Finally, working RNs seeking career progression can consider online rn-bsn programs without clinicals, allowing them to earn their BSN degree fully online without the need for on-site clinical hours.

These pathways demonstrate the broad educational possibilities available online, helping you chart a flexible and fulfilling healthcare career.

Best Scientists Citing Alba A. Brandes

Trending Scientists

Recently Published Articles